中华胃肠外科杂志
中華胃腸外科雜誌
중화위장외과잡지
CHINESE JOURNAL OF GASTROINTESTINAL SURGERY
2013年
4期
336-339
,共4页
李琨%张彩凤%夏永华%李贞娟%韩宇
李琨%張綵鳳%夏永華%李貞娟%韓宇
리곤%장채봉%하영화%리정연%한우
溃疡性结肠炎%微生态制剂%白细胞介素10
潰瘍性結腸炎%微生態製劑%白細胞介素10
궤양성결장염%미생태제제%백세포개소10
Ulcerative colitis%Probiotics%Interleukin-10
目的 探讨微生态制剂对溃疡性结肠炎(UC)的治疗效果及其作用机制.方法 前瞻性入组2007年5月至2010年6月间新乡医学院第一附属医院收治的60例UC患者,按随机数字表法分为金双歧组、畅美组和联合组(金双歧联合畅美),每组各20例.分别予以金双歧2.0 g口服、2次/d,畅美1.0 g口服、3次/d,及两种药物联合应用,疗程为24个月.治疗前及治疗后24个月对各组患者进行临床症状评分、内镜分级评分以及结肠炎性反应评分;并通过免疫组织化学染色和酶联免疫双抗体夹心法分别检测结肠黏膜及血清中的白细胞介素10(IL-10)含量.结果 联合组患者治疗后24个月,临床症状评分(12.5±2.1比2.3±0.8,P=0.016)、内镜分级评分(3.02±0.17比0.25±0.13,P=0.032)和炎性反应评分(2.63±0.19比0.77±0.16,P=0.028)均显著优于治疗前;而金双歧组和畅美组治疗前后各项评分的差异均无统计学意义(均P>0.05).联合组患者治疗24个月时,IL-10在结肠黏膜中的阳性表达率[85%(17/20)比55%(11/20),P=0.038]和在血清中的表达水平[(17.4±2.2) ng/L比(12.8±2.2) ng/L,P=0.015]均显著高于治疗前;而金双歧组和畅美组治疗前后IL-10表达水平的差异均无统计学意义(均P>0.05).结论 金双歧联合畅美治疗UC疗效肯定,其治疗作用可能与促进IL-10表达升高有关.
目的 探討微生態製劑對潰瘍性結腸炎(UC)的治療效果及其作用機製.方法 前瞻性入組2007年5月至2010年6月間新鄉醫學院第一附屬醫院收治的60例UC患者,按隨機數字錶法分為金雙歧組、暢美組和聯閤組(金雙歧聯閤暢美),每組各20例.分彆予以金雙歧2.0 g口服、2次/d,暢美1.0 g口服、3次/d,及兩種藥物聯閤應用,療程為24箇月.治療前及治療後24箇月對各組患者進行臨床癥狀評分、內鏡分級評分以及結腸炎性反應評分;併通過免疫組織化學染色和酶聯免疫雙抗體夾心法分彆檢測結腸黏膜及血清中的白細胞介素10(IL-10)含量.結果 聯閤組患者治療後24箇月,臨床癥狀評分(12.5±2.1比2.3±0.8,P=0.016)、內鏡分級評分(3.02±0.17比0.25±0.13,P=0.032)和炎性反應評分(2.63±0.19比0.77±0.16,P=0.028)均顯著優于治療前;而金雙歧組和暢美組治療前後各項評分的差異均無統計學意義(均P>0.05).聯閤組患者治療24箇月時,IL-10在結腸黏膜中的暘性錶達率[85%(17/20)比55%(11/20),P=0.038]和在血清中的錶達水平[(17.4±2.2) ng/L比(12.8±2.2) ng/L,P=0.015]均顯著高于治療前;而金雙歧組和暢美組治療前後IL-10錶達水平的差異均無統計學意義(均P>0.05).結論 金雙歧聯閤暢美治療UC療效肯定,其治療作用可能與促進IL-10錶達升高有關.
목적 탐토미생태제제대궤양성결장염(UC)적치료효과급기작용궤제.방법 전첨성입조2007년5월지2010년6월간신향의학원제일부속의원수치적60례UC환자,안수궤수자표법분위금쌍기조、창미조화연합조(금쌍기연합창미),매조각20례.분별여이금쌍기2.0 g구복、2차/d,창미1.0 g구복、3차/d,급량충약물연합응용,료정위24개월.치료전급치료후24개월대각조환자진행림상증상평분、내경분급평분이급결장염성반응평분;병통과면역조직화학염색화매련면역쌍항체협심법분별검측결장점막급혈청중적백세포개소10(IL-10)함량.결과 연합조환자치료후24개월,림상증상평분(12.5±2.1비2.3±0.8,P=0.016)、내경분급평분(3.02±0.17비0.25±0.13,P=0.032)화염성반응평분(2.63±0.19비0.77±0.16,P=0.028)균현저우우치료전;이금쌍기조화창미조치료전후각항평분적차이균무통계학의의(균P>0.05).연합조환자치료24개월시,IL-10재결장점막중적양성표체솔[85%(17/20)비55%(11/20),P=0.038]화재혈청중적표체수평[(17.4±2.2) ng/L비(12.8±2.2) ng/L,P=0.015]균현저고우치료전;이금쌍기조화창미조치료전후IL-10표체수평적차이균무통계학의의(균P>0.05).결론 금쌍기연합창미치료UC료효긍정,기치료작용가능여촉진IL-10표체승고유관.
Objective To evaluate the efficacy of probiotics on the treatment outcomes of ulcerative colitis,and explore its possible mechanism.Methods According to the table of random number,60 ulcerative colitis patients in our hospital were enrolled prospectively and divided into 3 groups:Golden Bifid group,Changmei group,combination group (Golden+ Changmei).Patients in Golden Bifid group received Golden Bifid 2.0 g,bid,those in Changmei group received Changmei 1.0 g,tid,and those in combination group received the above two drugs for 24 months.The clinical symptom score,colon mucosa inflammation score and endoscopic grade score were calculated and compared.IL-10 in mucosa and serum was determined by immunohistochemistry and doubleantibody sandwich ELISA.Results In combined group after 24 months of treatment,clinical symptom score (12.5±2.1 vs.2.3±0.8,P=0.016),endoscopic classification score (3.02±0.17 vs.0.25±0.13,P=0.032),inflammatory reaction score (2.63±0.19 vs.0.77±0.16,P=0.028) were significantly higher than those before treatment.While the scores differences of before and after treatment in Gold Bifid group and Changmei group were not statistically significant(P>0.05).IL-10 in serum [(17.4±2.2) ng/L vs.(12.8±2.2) ng/L,P=0.015] and colon mucosa [85%(17/20) vs.55%(11/20),P=0.026] in combination group were significantly higher than those before treatment.The differences in IL-10 expression level before and after treatment were not statistically significant in the Gold Bifid group and Changmei group (P>0.05).Conclusion Golden Bifid combined with Changmei as microbial ecological agents has a positive efficacy on mild to moderate ulcerative colitis,which may be associated with the up-regulation of IL-10 expression.